Mathieu Rousseau

839 posts

Mathieu Rousseau banner
Mathieu Rousseau

Mathieu Rousseau

@RousseauMC

Thoracic, Trauma & Foregut Surgery @CIUSSSNMTL & @McGillU, Chief of Thoracic @ Sacré-Coeur Hospit, Assist Professor @UMontreal, Alum @Stanford

Montréal, Québec Katılım Aralık 2011
993 Takip Edilen614 Takipçiler
Mathieu Rousseau retweetledi
Lung Cancer Europe
Lung Cancer Europe@LungCancerEu·
The VALUE Trial team shows that same-day discharge after VATS lung resection can be done safely for carefully selected patients. Strong work from @DoctorJSpicer, @MThoracics, @LyndonCWalsh, @filippog92 & @MeravRokah 👏. In LuCE’s 5th Report, 6 in 10 people said family life was heavily affected by #lungcancer - time away from loved ones adds to the challenge. 📄 Spicer et al., JTCVS 2025 🔗 sciencedirect.com/science/articl… #ThoracicSurgery #LCSM
Lung Cancer Europe tweet media
English
0
9
20
1.3K
Mathieu Rousseau retweetledi
Jonathan Spicer MD PhD
Jonathan Spicer MD PhD@DoctorJSpicer·
Super proud of our team @MThoracics for putting together this trial showing that same day discharge after lung resection, specifically anatomic lung resection, is both safe and feasible! Would not have been possible without the hard work of @LyndonCWalsh and @MeravRokah, as well as our nurses Erin Cronin and Tia Wallace. @sara_najmeh is now leading our standard of care pathway implementation! sciencedirect.com/science/articl…
English
4
8
51
7.9K
Mathieu Rousseau retweetledi
Allison Chang
Allison Chang@aebchang·
@DoctorJSpicer just articulated what I think has been the theme of the paradigm changing work presented at #ASCO24, “It’s more about disease biology than the anatomical extent.” This is absolutely how I am beginning to think about lung cancer—staging is not a complete prognostic indicator.
English
2
4
8
1.2K
Mathieu Rousseau retweetledi
Lorenzo Ferri MD PhD
Lorenzo Ferri MD PhD@LFerri123·
ESOPEC trial It’s been a long 15 year journey, but so nice to see Docetaxel triplets come on top for the benefit of our patients! CROSS just doesn’t work for GEA-EAC- radiation compensates for poor surgical control (trans-hiatal) and CM577 compensates for poor systemic control
Lorenzo Ferri MD PhD tweet media
English
2
18
60
13.6K
Mathieu Rousseau retweetledi
Krishan Jethwa
Krishan Jethwa@KrishanJethwa·
🚨🚨🚨 #ESOPEC🚨🚨🚨 🔥Practice shifting trial🔥 Patients with resectable, locally advanced, esophagus/GEJ adenocarcinoma Randomized Peri-op FLOT (FLOT4) vs Pre-operative chemoradiation (CROSS) Congrats to the study investigators! Let’s dive in! #ASCO24 @MayoRadOnc 1/
Krishan Jethwa tweet mediaKrishan Jethwa tweet mediaKrishan Jethwa tweet mediaKrishan Jethwa tweet media
English
12
137
295
118.9K
Mathieu Rousseau retweetledi
ASCO
ASCO@ASCO·
New from the Plenary Session at #ASCO24: ESOPEC helps settle debate on superiority of perioperative #chemo (FLOT) vs neoadjuvant chemoradiotherapy (CROSS) in esophageal cancer with 29-month improvement in OS with FLOT vs CROSS: brnw.ch/21wKmPS #ASCODailyNews #esocsm
ASCO tweet media
English
0
23
50
8.2K
Mathieu Rousseau retweetledi
Télé-Québec
Télé-Québec@telequebec·
«De garde 24/7» vous revient pour une 9e saison dans de tous nouveaux lieux. Découvrez les équipes de l'hôpital Sacré-Coeur de Montréal, l'hôpital Le Royer de Baie-Comeau et de l'EVAQ. 📺Jeudi 20h, dès le 7 septembre 👉youtu.be/4pi4aFDfjjo
YouTube video
YouTube
Télé-Québec tweet media
Français
1
5
26
2.5K
Mathieu Rousseau retweetledi
Evan Wong, MD, MPH, FRCSC, FACS
Evan Wong, MD, MPH, FRCSC, FACS@evanwongMDCM·
After 4 years of preparation, finally able to provide surgical care to our Inuit patient population within their communities. Sixteen satisfied patients treated this week who did not have to travel 1600km to Montreal for their surgeries. #Puvirnituq
Evan Wong, MD, MPH, FRCSC, FACS tweet media
English
6
16
109
8.7K
Mathieu Rousseau
Mathieu Rousseau@RousseauMC·
That’s why I tell my patients Lung Cancer is the new Breast Cancer. ⁦@ASCO⁩ That’s where we are going too!
Mathieu Rousseau tweet media
English
0
0
3
682
Eric K. Singhi, MD
Eric K. Singhi, MD@lungoncdoc·
Important to consider, what happens to the 15-20% of patients on these trials who do not make it to surgery? #lcsm #ASCO23
Eric K. Singhi, MD tweet media
English
2
4
11
1.4K
Mathieu Rousseau
Mathieu Rousseau@RousseauMC·
@Tony_Calles Was AEGEAN screening failure rate presented at AACR? The surgical eligibility criteria were even more strict with AEGEAN. Anticipated pneumonectomy were excluded which lead to many screening failure at our site.
Chicago, IL 🇺🇸 English
0
1
2
387
Dr. Antonio Calles 🫁🚭
Dr. Antonio Calles 🫁🚭@Tony_Calles·
Is neoadjuvant Chemo-immunotherapy feasible for all your potentially operable stage II-III NSCLC patients in the clinic? In KN-671 trial, only 796/1364 patients fulfil the eligibility criteria. That’s 42% screening failure rate‼️#ASCO23 #LCSM
Dr. Antonio Calles 🫁🚭 tweet mediaDr. Antonio Calles 🫁🚭 tweet media
English
3
12
25
6.3K
Mathieu Rousseau
Mathieu Rousseau@RousseauMC·
Amazing talk by @DrMarkAwad @ASCO Cross trials comparisons of peri-op IO. Neoadj seems advantageous. The ❔remains,what to do with poor path responders? Frequent discussion at our TB, data is badly needed. Didn’t bring up radiation as an option for persistent N2. Thoughts?
Mathieu Rousseau tweet mediaMathieu Rousseau tweet media
English
0
0
0
438